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1. Introduction  
Last century, in 1907, Alois Alzheimer first described the disease that now bears his name, 
relating a 54-year-old female case with presenile dementia. Alzheimer’s disease (AD), an 
irreversible progressive neurodegenerative disorder, is actually the most common form of 
dementia. AD affects more than 24 million people all over the world, and is predicted to 
double every 20 years, becoming one of the medical burdens of our days. More than 90% of 
AD cases are sporadic late-onset, and have a complex idiopathic aetiology. The small 
number of early onset AD cases, is related to hereditary monogenic defects, and has 
provided important clues for understanding the AD pathology (Bertram, et al. 2007). 
Although the available drugs are able to delay the symptoms and progression of the disease 
and to positively influence the quality of life of the patients, at present there is still no cure 
for AD.  
AD is characterized clinically by progressive decline in cognitive function and 
neuropatologically by the presence of neuropil threads and neuron loss, in addition to the 
molecular hallmarks of neurofibrillar tangles and neuritic (or senile) plaques in the brain. 
Neuritic plaques are extracellular amyloid deposits found abundantly in the hippocampus, 
in the neocortex and in the amygdala of AD brains. These pathological brain changes may 
occur 20 to 30 years prior to the onset of the clinical symptoms and the symptomatic phase 
of AD can last from 5 to 12 years (DeKosky and Marek 2003). The extracellular neuritic 
plaque deposits of amyloid were first investigated by (Glenner and Wong 1984), when they 
purified microvascular amyloid deposits from AD brains, and provided a partial sequence 
of a 4kDa subunit protein, that they named amyloid-beta (Aǃ) peptide. Around the same 
time, the hyperphosphorylated tau (p-tau), a microtubule assembly protein, was identified 
as the main constituent of the neurofibrillar tangles (NFTs) that accumulate inside many 
neurons in AD brains (Grundke-Iqbal, et al. 1986). Amyloid deposition and neurofibrillar 
tangles, occur with some frequency in brains of young adults with Down's syndrome 
(Schochet, et al. 1973). The discovery that amyloid deposits in the brain from Down 
syndrome were composed of Aǃ peptide (Glenner and Wong 1984), as well as the cloning of 
the beta amyloid precursor protein (APP), with its localization to the chromosome 21 
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(Korenberg, et al. 1989), led the scientists to search AD-causing mutations in the APP gene. 
Since that, several mutations associated with familial early onset forms of AD have been 
described, either in the APP gene (Kowalska 2003) or in preselin 1 (PS1) or preselin 2 (PS2) 
genes (Bertram et al. 2007). Either PS1 or PS2 can be the catalytic subunit of Ǆ-secretase, 
which is the final endoprotease in the pathways that generate the Aǃ peptide (see section 2). 
All these findings led to the amyloid cascade hypothesis, articulated by John Hardy and 
others (Hardy and Higgins 1992), in which the accumulation of Aǃ peptide, generated from 
the proteolytic cleavage of APP in the brain, could trigger a complex downstream cascade 
that results in the symptoms of AD. This hypothesis states that gradual accumulation and 
aggregation of the hydrophobic Aǃ peptide initiates a cascade that leads to synaptic 
alterations, astrocytic and microglial activation, the modification of the soluble tau protein 
into insoluble paired helical filaments, and progressive neuronal loss associated with 
multiple neurotransmitter deficiencies and cognitive failure (Hardy and Selkoe 2002). The 
cascade hypothesis suggests that stopping or slowing formation of the Aǃ plaques would 
delay the onset of the disease symptoms. Aǃ is found in the extracellular fluids of the brain, 
including cerebrospinal fluid (CSF), and in the interstitial fluid surrounding neurons and 
glial cells in brain lobes (Seubert, et al. 1992; Vigo-Pelfrey, et al. 1993). Over the last years, 
several key proteins have been described as being implicated in Aǃ production and 
clearance, but further elucidation of the mechanisms involved in the process will be 
important for identifying new potential therapies to reduce Aǃ accumulation and combat 
AD. This book chapter reviews the production of Aǃ from APP and the proteins involved in 
its degradation and clearance .  
2. Generation of amyloid beta peptides  
The ǃ amyloid precursor protein, APP, takes a central position in AD pathogenesis, as it is 
processed by the sequential action of ǃ- and Ǆ-secretase, generating the Aǃ peptide, which is 
deposited as amyloid plaques in brains of AD individuals. APP is an integral membrane 
protein, with a large N-terminal extracellular domain and a short C-terminal cytoplasmatic 
domain, which is expressed ubiquitously in neuronal and non-neuronal cells. 
The human APP gene is located on chromosome 21 (Korenberg et al. 1989) and alternative 
splicing results in protein isoforms of various lengths: two isoforms predominant in non-
neuronal tissues (751- and 770-), and the 695-amino acid form, that is the predominant 
isoform in neurons (Kang and Muller-Hill 1990). APP belongs to a protein family that 
includes APP-like protein 1 (APLP1) and 2 (APLP2) (Eggert, et al. 2004), a group of type-I 
transmembrane proteins that are processed in the same fashion. APP is hydrolyzed into 
different fragments (Figure 1) during its intracellular trafficking, and these metabolites 
mediate various functions (Haass 2004; Haass and Selkoe 1993). APP is first cleaved by 
either ǂ- or ǃ-secretase at the ǂ- or ǃ-sites, respectively, which lie in the extracellular domain 
of the APP. These proteases compete for APP, originating: soluble APPǂ (sAPPǂ, for ǂ-
secretase) or soluble APPǃ (sAPPǃ, for ǃ-secretase), which are released to the extracellular 
space, and a membrane anchored C-terminal end (C83 for ǂ-secretase or C99 for ǃ-
secretase). Subsequently, in the lipid bilayer, Ǆ-secretase acts in the C-terminal end, C83 or 
C99. The Ǆ-cleavage of C83 generates the APP intracellular domain (AICD), with 6kDa, and 
the N-terminal peptide with 3kDa (p3) into the extracellular space. Ǆ-cleavage of C99, in a 
specific sequence (Aǃ domain) generates Aǃ peptide and the AICD. This pathway of APP 
processing by ǃ-secretase followed by Ǆ-secretase leading to Aǃ peptide is called the 
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amyloidogenic pathway. Aberrant and/or cumulative Aǃ production, have been postulated 
to be the main etiological basis of AD. The alternative pathway of APP processing by ǂ-
secretase followed by Ǆ-secretase, in which no Aǃ is formed, is termed nonamyloidogenic 
pathway. 
 
 
Fig. 1. Schematic diagram of APP processing (not drawn in scale). TM-transmembrane;EC- 
extracelular; IC- intracellular 
Aǃ is a ~4kDa peptide with 38 to 43 amino acids, depending on the site of Ǆ-secretase 
cleavage. Aǃ peptide is normally produced by cells and under physiological conditions 
there are two major species: Aǃ40 and Aǃ42. The major species produced is Aǃ40 and 
corresponds to 90% of the total Aǃ peptide. The minor species produced, Aǃ42, is more 
prone to aggregation due to two additional hydrophobic amino acids, and therefore it is the 
predominant species accumulated in AD brain plaques.  
A number of proteins influence the subcellular trafficking itinerary of APP and ǃ-secretase 
between the cell surface, endosomes and the Trans-Golgi-Network (TGN). APP is 
synthesized in the endoplasmic reticulum (ER) and is transported through the Golgi 
apparatus to the TGN, where the highest concentration is found in steady state neurons 
(Greenfield, et al. 1999). From TGN,  the APP can be transported, in TGN-derived vesicles, 
to cell surface where it is either cleaved by ǂ-secretase to produce sAPPǂ, or internalized via 
the endosomal-lysosomal pathway (Caporaso, et al. 1994). The Aǃ peptide is generated 
either in the ER and TGN (Greenfield et al. 1999), as in the endosomal/lysosomal system 
(Haass and Selkoe 1993). Available evidence suggests that co-residence of APP and ǃ-
secretase in the endosomal compartments promotes amyloidogenesis. Retrograde transport 
of APP, out of the endosome to the TGN, reduces Aǃ production, while APP routed to, and 
kept at the cell surface, enhances its non-amyloidogenic processing (Tang 2009). 
Very little is known about the physiological function of APP and its proteolytic products. 
APP knockout mice (KO) are viable and fertile, showing a slight abnormal phenotype 
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(Dawson, et al. 1999). APLP1 and APLP2 KO mice are also viable and fertile, but 
APP/APLP2 and APLP1/APLP2 double null mice and APP/APLP1/APLP2 triple null 
mice show early postnatal lethality (Heber, et al. 2000; von Koch, et al. 1997). APP/APLP1 
double null mice are viable, suggesting redundant functions of amyloid precursor protein 
family members (Heber et al. 2000). Putative suggested roles for APP include trafficking, 
neurotrophic signalling, control of cell adhesion, neuritic outgrowth and synaptogenesis, 
apoptosis and transcription regulation (Zheng and Koo 2006). As APP is proteolysed in the 
cell, the net effect of full-length APP on cellular activity may be a combination of the 
function of its proteolytic products, depending on the proportion levels of each of them.  
2.1 Alpha-secretase 
APP is cleaved by ǂ-secretase in the center of Aǃ domain, precluding Aǃ peptide 
generation, and a soluble domain of APP is released: sAPPǂ. Three related proteases, all 
from the ADAM family, had been suggested to exert the ǂ-secretase activity: ADAM-9, 
ADAM-10 and ADAM-17 (Asai, et al. 2003). Like full length APP, members of the ADAM 
family (a desintegrin and metalloprotease family) are type-I transmembrane proteins, 
possessing both potential adhesion and protease domains. Several studies suggested ǂ-
secretase activity for ADAM-9. However, as RNAi of ADAM-9 has no effect in sAPPǂ 
generation (Kuhn, et al. 2010), ADAM-9 seems to be involved only in regulated ǂ-cleavage 
and not in constitutive ǂ-secretase activity. Different studies strongly suggest that ADAM-
10 is the main constitutive ǂ-secretase that is active at the cell surface (Lammich, et al. 1999) 
(Jorissen, et al. 2010), but there may exist some functional redundancy in ǂ-cleavage by the 
ADAM protease family. ADAM-17 is an 824 amino acid polypeptide containing a secretory 
signal sequence, a desintegrin domain and a metalloprotease domain, that also seems to be 
involved in regulated ǂ-secretase activity (Merlos-Suarez, et al. 2001). 
sAPPǂ has important roles in neuronal plasticity/survival, stem cell proliferation in CNS, 
and  is able to rescue the abnormalities of APP deficient mice, indicating that most of APP´s 
physiological function is mediated by sAPPǂ (Zhang, et al. 2011). 
2.2 Beta-secretases: BACEs 
ǃ-secretase cleavage is the first critical step in the APP amyloidogenic pathway, and 
increased ǃ-secretase activity levels have been correlated with brain Aǃ deposition in late 
onset AD patients (Li, et al. 2004). Aǃ peptide is generated from APP by a sequential two-
step proteolytic process involving ǃ- and Ǆ-secretases (Haass 2004), being BACE 1 (ǃ-site 
APP cleaving enzyme 1) the major ǃ-secretase in the cell (Vassar, et al. 1999). BACE1 is a 
member of the pepsin family of aspartyl proteases, and its activity on APP generates the 
membrane bound C-terminal fragment (CTFǃ or C99). BACE1 requires acidic environment 
for optimal activity and cleaves APP at the known ǃ-site locations, Asp1 and Glu11. 
Overexpression of BACE1 induces cleavage of APP at ǃ-sites and is mainly found in the 
early Golgi, late Golgi/early endosomes and endosomes with acidic environment.  BACE1 is 
also found at the cell surface (Huse, et al. 2002; Vassar et al. 1999). 
BACE2 is an additional ǃ-secretase, mapped in 21q22.3 region (Solans, et al. 2000), that also 
cleaves ǃ-secretase substrates. However, BACE2 expression in neurons is lower than BACE1 
(Bennett, et al. 2000). BACE1 null mice died in the first weeks and those that survived, were 
smaller, presented hyperactive behaviour, were affected by hypomyelination of peripheral 
nerves and had altered neurological behaviours such as elevated pain sensitivity 
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(Dominguez, et al. 2005). BACE2 KO mice are healthy overall, while a deficiency of both 
BACE1 and BACE2 enhanced the BACE1 KO lethality phenotype, suggesting functional 
redundancy  (Dominguez et al. 2005).  
Cathepsin B has been proposed as another ǃ-secretase. Although its inhibition has been found 
to reduce Aǃ production, its physiological activity is not well established (Hook, et al. 2009). 
2.3 The gamma secretase complex  
Ǆ-secretase is a protein complex, of high molecular weight,  responsible for the membrane 
cleavage of the APP C-terminal remnants after cleavage by either ǂ- or ǃ-secretase (C83 and 
C99, respectively). The cleavage of C83 and C99 by Ǆ-secretase generates p3 and the Aǃ 
peptide, respectively. In addition to C83 and C99 peptides, several non-APP substracts are 
cleaved by Ǆ-secretase and all of them are type-I transmembrane proteins that require 
ectodomain shedding as a prerequisite to Ǆ-secretase cleavage (Haapasalo and Kovacs 2011). 
Ǆ-secretase complex comprises four core components which include: presenilin (PS1 or PS2), 
nicastrin, anterior pharynx-defective-1 (APH-1), and presenilin enhancer-2 (PEN2) 
(Kimberly and Wolfe 2003; Takasugi, et al. 2003). All of these four core components of Ǆ-
secretase are necessary for the enzymatic activity of the complex. PS1 and PS2 are two 
presenilin homologs, and several mutations in the corresponding genes have been described 
as the major cause of familial AD cases (Bertram et al. 2007). Different kinds of experimental 
evidences suggest that presenilins are transmembrane proteins with crucial catalytic roles in 
Ǆ-secretase activity (Zhang et al. 2011). Nicastrin, other component of Ǆ-secretase, is a type-I 
transmembrane glycoprotein considered the scaffolding protein of the complex (Vassar and 
Citron 2000). Finally, the other two components of Ǆ-secretase are: APH-1, that interacts 
with nicastrin to form a stable intermediate in the early assembly stages of the complex and 
PEN-2, that regulates PS endoproteolysis (Vassar and Citron 2000). Besides the four 
components of Ǆ-secretase complex, some factors, playing a modulatory role, have been 
described. Example of that is CD147 that when down regulated increases Aǃ production 
and TMP21/p23 that regulates Ǆ-cleavage (Zhang et al. 2011).  
Experimental evidences support the idea that Ǆ-secretase resides in ER, Golgi-TGN, 
endosomes and intermediate compartments, most of which (except TGN) do not correspond 
to the main localizations of APP (Cupers, et al. 2001). 
3. Enzymes and peptides involved in amyloid-beta degradation and clearence  
The clearance of Aǃ in the human central nervous system (CNS), is roughly 8% of total 
production per hour. It is controlled by Aǃ degradation in the brain and by its efflux from 
the CNS to the peripheral circulation through the blood-brain barrier or the blood-
cerebrospinal fluid barrier (Zlokovic 2004). The high clearance of Aǃ is in part due to the 
presence of cryptidases in several cellular compartments and reduction of Aǃ degradation 
by these enzymes may be implicated in the progression of AD cases.  Aǃ accumulation, and 
the concomitant formation of amyloid plaques observed in AD brains occurs in the 
extracellular space. It is also in this compartment, that Aǃ can be degraded by cell surface 
and/or secreted cryptidases, such as insulin degrading enzyme and neprylisin. The 
subcellular distribution of Aǃ degrading cryptidases is a strong indicator that Aǃ 
degradation can be controlled at multiple subcellular compartments, such as the 
mitochondria, ER, Golgi, endosomes and lisossomes (Malito, et al. 2008).  
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In the brain, Aǃ metabolism is mainly regulated by the activity of neprilysin (NEP) and 
insulin-degrading enzyme (IDE), but presequence peptidase, endothelin converting enzyme 
(ECE),  angiotensin-converting enzyme (ACE), the uPA/tPA- plasmin system  and matrix 
metalloproteinases are also involved in the process (Table 1). In addition, some proteins as 
transthyretin (TTR), gelsolin,  alpha2-macroglobulin and apolipoprotein E do also play an 
important role in Aǃ clearance and degradation. Some of them do actually have a direct 
function in Aǃ catabolism such as TTR, plasmin, and gelsolin, which have the capacity to 
cleave the peptide, others because their interaction with Aǃ enable its degradation or 
prevent its neurotoxicity as it is the case of alpha-2-macroglobulin and apolipoprotein E 
(Table 2).  
 
Enzymes Function Brain distribution References 
IDE 
Hydrolises peptide 
bonds of Aǃ40 and 
Aǃ42 
Neurons, microglia, 
endothelial cells, 
choroid plexus 
epithelial cells 
(Bora et al. 2010; Bora 
and Prabhakar 2010; 
Malito et al. 2008) 
NEP  
Hydrolises peptide 
bonds of Aǃ42 
Neurons, microglia, 
endothelial cells, 
choroid plexus 
epithelial cells  
(Malito et al. 2008; 
Meilandt et al. 2009) 
PreP 
Hydrolises peptide 
bonds of Aǃ40 and 
Aǃ42 in 
mitochondria 
 (Falkevall et al. 2006) 
ECE 
Hydrolises peptide 
bonds of Aǃ40 and 
Aǃ42 
Neurons, astrocytes, 
endothelial cells 
(Miners et al. 2008b) 
ACE 
Converts Aǃ42 to 
Aǃ40 
Cleaves Aǃ40 
Neurons,  
endothelial cells, 
choroid plexus 
epithelial cells 
(Miners et al. 2008a; Zou 
et al. 2007) 
Plasmin 
Degrades aggregated 
and non-aggregated 
Aǃ40 and Aǃ42 
Inhibits Aǃ 
fibrillogenesis 
Neurons, microglia 
(Tucker et al. 2002; 
Tucker et al. 2000b) 
MMP-2 
Hydrolises peptide 
bonds of Aǃ40 and 
Aǃ42 
Beta-secretase 
activity 
Microglia, 
astrocytes, Schwann 
cells 
(Miners et al. 2008a) 
MMP-9 
Hydrolises peptide 
bonds of Aǃ40 and 
Aǃ42 and aggregated 
Aǃ fibrils 
Neurons, 
endothelial cells 
(Miners et al. 2008a; Yan 
et al. 2006) 
Table 1. Functions and brain distribution of key enzymes in Aǃ clearance.  
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Key players Function 
Brain 
distribution 
References 
TTR 
Hydrolises peptide 
bonds of Aǃ40 and 
Aǃ42, and 
aggregated Aǃ 
oligomers and fibrils 
choroid plexus 
epithelial cells 
meninges 
(Costa et al. 2008; 
Schwarzman et al. 1994) 
Gelsolin 
Inhibits fibrillization 
of Aǃ 
and defibrillates 
preformed fibrils 
Oligodendrocyte
s, microglia, 
choroid plexus 
epithelial cells 
(Chauhan et al. 2008;  
Ray et al. 2000) 
Alpha-2 
macroglobulin 
Aǃ carrier, binds Aǃ 
protecting it from 
proteolysis, reduces 
Aǃ aggregation and 
fibril formation 
astroglia 
(Du et al. 1998;  
Du et al. 1997) 
Apo E 
Binds Aǃ enhancing 
the proteolytic 
activity of NEP, and 
IDE 
Astrocytes, 
neurons, 
microglia 
(Jiang et al. 2008) 
MT-2 
Diminishes Aǃ 
binding to TTR 
Prevents copper 
mediated 
aggregation of Aǃ 
Cortical neurons 
(Chung et al. 2010;  
Martinho et al. 2010) 
MT-3 
Increases Aǃ binding 
to TTR 
Inhibits formation of 
Aǃ aggregates 
Cortical neurons 
(Irie and Keung, 2001, 2003;  
Martinho et al. 2010) 
Table 2. Functions and brain distribution of key proteins in Aǃ clearance. 
3.1 IDE – Insulin degrading enzyme  
Insulin degrading enzyme (IDE) is  a ~ 110 kDa  zinc-containing metalloendopeptidase 
that degrades monomeric forms of Aǃ peptides and insulin, which has also high 
nanomolar affinity for other substrates with different sequences and structures. The 
common features of IDE substrates are that they are all amyloidogenic in nature. So, 
besides Aǃ and insulin, IDE also cleaves, insulin-like growth factor 2, atrial natriuretic 
peptide, bradykinin, endorphin, and glucagon. However,  in vivo relevance of this 
degrading activity has only been demonstrated for Aǃ and insulin (Malito et al. 2008). 
Interestingly, patients with type 2 diabetes are under an increased risk of AD. In 
addition, Aǃ is a direct competitive inhibitor of insulin binding and action, and this is a 
likely justification for the increased levels of Aǃ observed in insulin resistant AD patients 
(Xie, et al. 2002). This dual effect of IDE stresses the importance of the development  
of inhibitors and activators of its activity for the treatment of diabetes and AD, 
respectively.  
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The first evidences of the capacity of IDE to degrade Aǃ were reported by Kurochkin and 
Goto (1994) who identified a protein of  110,000 Da present in cytosol fractions from rat 
brain and liver that cross-linked to 125I-labeled synthetic Aǃ.  A few years later IDE was 
actually identified as the main soluble Aǃ degrading enzyme in human brain and in 
neuronal cell cultures, where its action takes places in the extracellular milieu (McDermott 
and Gibson 1997).   Besides its ability to degrade Aǃ, IDE activity is also  associated with 
oligomerization of synthetic Aǃ at physiological levels in the conditioned media of cultured 
cells (Qiu, et al. 1998). In addition, evidence that membrane-associated and secreted IDE 
isoforms carry out the degradation and clearance of Aǃ secreted by neurons and microglia 
was provided a couple of years later (Bertram, et al. 2000). 
IDE is composed of four homologous domains that share 15–24% sequence similarity. These 
domains form two functional N- and C-terminal domains that are joined by an extended 28 
amino acid residue loop, creating a large catalytic chamber which can accommodate 
substrates of the order of 6 kDa.  Substrate binding is assisted by the C-terminal domain 
and, its hydrolysis occurs at the N-terminal domain (Li, et al. 2006). The active site of IDE 
encompasses the His-Glu-aa-aa-His sequence and requires zinc.  IDE  enzyme hydrolyses 
several peptide bonds of both Aǃ40 and Aǃ42, but is particularly efficient at hydrolysing the 
Lys28-Gly29 peptide bond followed by the Phe19-Phe20 and His14-Gln15  bonds of these 
substrates (Bora, et al. 2010; Bora and Prabhakar 2010).  
IDE is expressed by cortical and subcortical neurons, and has been detected in the cytoplasm 
of the three major components of the vascular wall: endothelial cells, pericytes and smooth 
muscle cells (Dorfman, et al. 2010; Gao, et al. 2004).  IDE is also expressed towards the apical 
surface of the choroid plexus tissue where its inhibition leads to disrupted metabolism of Aǃ 
and its concurrent accumulation at the blood-CSF barrier (Behl, et al. 2009). Besides the 
cytoplasm, IDE is found in endosomes, on the cell surface, and in the extracellular milieu. 
The type of cell in the nervous system expressing IDE establishes whether it is secreted or 
associated with the cell surface. Primary mouse microglia and the BV-2 cell line are found to 
secrete IDE, but in primary hippocampal neurons and differentiated PC12 cells only 
membrane associated IDE has been found. IDE is also present in mitochondria, and in the 
dendrites of neurons (Malito et al. 2008). 
Evidence that IDE activity in AD brains is reduced compared to age-matched controls has 
been giving support to the hypothesis that  reduced IDE activity may contribute to Aǃ 
accumulation in the brain (Perez, et al. 2000). For example,  membrane-bound IDE protein 
concentrations and activity decrease during the conversion from mild cognitive impairment 
(MCI) to mild-severe AD in the hippocampus, which correlates negatively with brain Aǃ42 
content in MCI and in AD brain (Zhao, et al. 2007). Still, other studies indicate that IDE may 
be less important in the process of Aǃ clearance (Wang, et al. 2010). There is also evidence 
that in transgenic mice brain, Aǃ plaques induce cortical mRNA and protein levels of IDE in 
parallel with increased Aǃ40 and Aǃ42 production, suggesting a positive feedback 
regulatory mechanism of Aǃ regulation (Vepsalainen, et al. 2008). 
3.2 NEP – Neprilysin 
Neprilysin (NEP) is a 90–110 kDa plasma membrane glycoprotein of the neutral zinc 
metalloendopeptidase family. It consists of a short N-terminal cytoplasmic tail, a single 
transmembrane helix and a large C-terminal extracellular ectodomain. The ectodomain of 
neprilysin is largely made of ǂ-helices with six disulfide bridges and at least three N-
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glycosylation sites. The ectodomain  encompasses the catalytic site, with the conserved 
HExxH motif necessary for zinc coordination and a  proteolytic chamber (Malito et al. 2008).  
NEP is widely expressed in several tissues such as the brush-border of intestinal and kidney 
epithelial cells, neutrophils, thymocytes, lung, prostate, testes, and brain. In the brain, it is 
expressed on the plasma membranes of neurons, pre- and post-synaptically, and is most 
abundant in the nigrostriatal pathway,  and in brain areas vulnerable to amyloid plaque 
deposition, such as the hippocampus (Wang, et al. 2006).  It is also expressed in the tunica 
media and endothelium of cortical and leptomeningeal blood vessels where it participates in 
the regulation of the vascular tone, and in pyramidal neurons.  NEP is also involved in the 
regulation of neuropeptide signalling (Dorfman et al. 2010; Miners, et al. 2008b).  
NEP has been implicated in the degradation of Aǃ. It degrades Aǃ42 in vivo, and when NEP 
is inhibited, Aǃ degradation in rat hippocampus is blocked with a concomitant increase of 
Aǃ42 plaques in this brain region, and in the cortical region outside the hippocampus. In 
addition, the capacity to degrade Aǃ42 of exogenous origin is severely compromised in NEP 
knockout homozygote mice in which the levels of Aǃ40 and Aǃ42 remain very high. These 
studies are corroborated by correlative studies in patients with sporadic AD and healthy age 
matched controls. Overexpression of NEP in brains of human amyloid precursor protein 
(hAPP) transgenic mice decreases overall Aǃ levels and amyloid plaque burdens by 50% 
and effectively prevented early Aǃ deposition in the neocortex and hippocampus. However, 
it did not reduce levels of Aǃ oligomers or improved deficits in spatial learning and 
memory. The differential effect of NEP on plaques and oligomers suggests that NEP-
dependent degradation of Aǃ affects plaques more than oligomers and that these structures 
may form through distinct assembly mechanisms (Meilandt, et al. 2009). Moreover, the 
expression of NEP on the surface of leukocytes, trough lentivirus  transplantation of bone 
marrow cells, reduced soluble brain Aǃ  levels by ~30% and lowered the accumulation of 
Aǃ peptides by 50–60% when transplantation was performed at both young and early adult 
age. This peripheral NEP expression reduced amyloid dependent performance deficits of 
these animals in the Morris Water Maze (Guan, et al. 2009). Ex-vivo gene delivery of a 
soluble form of NEP, via fibroblasts, into transgenic APP mice also demonstrated increased 
clearance of plaques. Interestingly, mRNA and protein levels of NEP can be induced by 
intracranial injections of Aǃ42, which also reduced the accumulation of amyloid plaques 
(Malito et al. 2008). Microglia from old PS1-APP mice, but not from younger mice, have a 
twofold to fivefold decrease in expression of NEP,  compared with their littermate controls 
(Hickman, et al. 2008). Despite all the evidence sustaining the proteolytic action of NEP on 
Aǃ, the molecular basis of the interaction between NEP and Aǃ remains largely unexplained 
because the volume of the proteolytic chamber of NEP is about half the size of Aǃ (Malito et 
al. 2008). 
3.3 Presequence peptidase  
Presequense peptidase (PreP) is a 110 kDa metalloprotease, ubiquitously expressed, but 
with higher abundance in heart and skeletal muscle. It is responsible for degradation of 
targeting peptides, which have been cleaved off inside the mitochondrial matrix after 
protein import, but it also cleaves other unstructured peptides up to 65 amino acids (Stahl, 
et al. 2002).  More recently, PreP was shown to completely degrade Aǃ40 and Aǃ42, which 
are present in mitochondria. More relevance is added to this action of PreP as it has been 
shown that hPreP is actually the only protease responsible for degradation of Aǃ in the 
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mitochondria (Falkevall, et al. 2006) and Aǃ-induced mitochondrial toxicity has been 
associated with AD (Tillement, et al. 2011).  
Human PreP consists of 4 domains, creating two halves connected by a hinge region. The 
two halves can create a large catalytic chamber of 10 000 Ǻ where Aǃ fits. The inverted zinc-
binding motif is located in the N-terminal region, but also includes  residues located in the 
C-terminal half, about 800 amino acids distant from the zinc-binding motif (Johnson, et al. 
2006).  Unlike IDE, PreP cannot degrade insulin, making PreP a better therapeutic agent 
candidate than IDE as its use would preclude deleterious side effects associated with the 
degradation of insulin. Another interesting feature of PreP is that its proteolytic activity 
against Aǃ is abolished under oxidizing conditions, probably due to the formation of a 
disulphide bridge between Cys90 and Cys527 that inhibits the substrate from entering the 
catalytic chamber. These findings indicate a possible inhibition of hPreP under elevated ROS 
production in mitochondria implicated in AD, and might therefore be relevant in this 
disease (Alikhani, et al. 2009).  
3.4 ECE – Endothelin converting enzyme  
Endothelin-converting enzymes 1 and 2 (ECE-1 and ECE-2) were originally implicated in the 
processing of pro-hormone forms of endothelin. They are type II integral membrane zinc 
metalloendopeptidases that are primarily localized to the endothelium throughout the 
human vasculature. They share common catalytic substrates and are responsible for 
cleaving big endothelins to produce potent vasoconstrictor endothelins (Miners, et al. 2008a; 
Miners et al. 2008b).  
ECE sequences and domain organization are similar to NEP’s and are also capable of 
degrading Aǃ in vitro and in vivo (Eckman, et al. 2001). Homozygous knockouts for ECE-1 
are lethal and heterozygous animals show an increased amount of Aǃ40 and Aǃ42 in the 
brain. Homozygous ECE-2 knockout mice show a gene dose dependent increase of both 
forms of Aǃ in the brain as well (Eckman, et al. 2006; Eckman, et al. 2003).  
ECE-1 is present in neurons, specifically in pyramidal neurons of the hippocampus and 
layer V of the neocortex, and to a less extent in astrocytes (Sluck, et al. 1999). In mice, ECE-2 
is largely confined to the brain; in the rat brain, ECE-1 occurs in the cerebrovascular 
endothelium, whereas ECE-2 is predominantly neuronal, with special incidence on 
hippocampal pyramidal neurons (Miners et al. 2008a; Miners et al. 2008b). 
There is evidence of significant decrease in ECE-2 gene expression in AD patients 
(Weeraratna, et al. 2007). The contribution of ECE-1 to the accumulation of Aǃ or reduction 
in local microvascular blood flow in AD seems to be detrimental, with abnormal production 
of ET-1 being more likely to reflect Aǃ -mediated upregulation of ECE-2 (Palmer, et al. 
2010). 
3.5 ACE – Angiotensin-converting enzyme 
Angiotensin-converting enzyme (ACE) is a membrane-bound zinc metalloprotease 
expressed in blood vessels throughout the body. ACE is extremely important for the 
regulation of fluid homeostasis and blood pressure. It converts angiotensin I to the potent 
vasoconstrictor angiotensin II.  Within the brain, ACE has been detected in cortical 
pyramidal neurons and in the cerebral vasculature. Its highest levels occur in 
circumventricular organs, such as the subfornical organ, area postrema, and the median 
eminence but  was detected in other areas such as the caudate nucleus, putamen, substantia 
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nigra pars reticularis, nucleus of the solitary tract, dorsal motor nucleus, median preoptic 
nucleus, and choroid plexus in rat, human, rabbit, sheep and monkey (Miners et al. 2008a). 
ACE has two homologous domains, each having a functional active site. The N-domain of 
ACE is responsible for converting Aǃ42 to Aǃ40, whereas the angiotensin-converting 
activity is found predominantly in the C-domain of ACE. N-linked glycosylation is essential 
for both Aǃ42 to Aǃ40 conversion and angiotensin-converting activities and protects ACE 
from proteolysis (Zou, et al. 2009). 
The first correlations between ACE and AD were found in 1985 by Zubenko and colleagues 
(Zubenko, et al. 1985)  who showed that the CSF of patients with moderate degrees of senile 
dementia of the AD type exhibited about half the ACE activity of  age and sex-matched 
control individuals, raising the possibility that ACE activity in the CSF could be an index of 
AD. In a posterior study, however,  no differences in ACE activity in the CSF were found 
between  AD patients and age matched controls raising some controversy on this issue 
(Konings, et al. 1993), but other studies reported reduced activity of ACE in  the parietal 
cortex of AD brains (Ichai, et al. 1994).  
ACE was found to significantly inhibit Aǃ aggregation in 2001 (Hu, et al. 2001).  The 
inhibition of aggregation was specifically blocked by preincubation of ACE with an ACE 
inhibitor, lisinopril. ACE degraded Aǃ by cleaving Aǃ40 at the site Asp(7)-Ser(8). Compared 
with Aǃ40, aggregation and cytotoxic effects of the degradation products Aǃ-(1-7) and Aǃ-
(8-40) peptides were reduced or virtually absent. These findings led to the hypothesis that 
previous associations of ACE genotype with AD susceptibility (Farrer, et al. 2000; Hu, et al. 
1999; Isbir, et al. 2001; Yang, et al. 2000)  could rely on its capacity to degrade Aǃ and 
prevent the accumulation of amyloid plaques in vivo. Besides Aǃ40 degradation, cellular 
expression of ACE also promotes degradation of naturally secreted Aǃ42, and leads to the 
clearance of both species (Hemming and Selkoe 2005). In addition, ACE also converts Aǃ42 
to Aǃ40 which is less neurotoxic (Zou, et al. 2007).  
Pharmacological inhibition of ACE with a widely prescribed drug, captopril, promotes the 
accumulation of cell-derived Aǃ in the media of APP expressing cells and questions if 
prescribed ACE inhibitors against hypertension could elevate cerebral Aǃ levels in humans 
(Hemming and Selkoe 2005). To address this question the ACE inhibitor captopril was 
administered to two lines of APP transgenic mice presenting low or high levels of Aǃ with 
associated plaque deposition. In both models, captopril did not affect cerebral Aǃ levels nor 
plaque deposition or peripheral Aǃ levels (Hemming, et al. 2007).  
Epidemiological data obtained from a male population, however, suggests that angiotensin 
receptor blockers are more efficient in reducing the incidence and progression of AD and 
dementia compared with ACE inhibitors or other cardiovascular drugs (Li, et al. 2010). 
However, there are strong indications that ACE inhibitors may reduce the risk for and 
progression of dementias (Shah, et al. 2009). Still, these effects remain rather  controversial, and 
prescription of ACE inhibitors against hypertension should be regarded with caution (Hajjar, 
et al. 2008; Kehoe and Wilcock 2007; Shah et al. 2009). Alternatively, ACE inhibitors could be 
designed to specifically target the angiotensin-converting C-domain, without inhibiting the 
Aǃ42 to Aǃ40-converting activity of ACE or increasing neurotoxic Aǃ42 (Zou et al. 2009).  
3.6 uPA/tPA-plasmin system  
Plasmin is a serine protease generated from the proteolytic cleavage of inactive 
plasminogen, by tissue-type (tPA) or by urokinase-type plasminogen activator (uPA). In the 
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brain, plasminogen is synthesized in neurons, whereas uPA and tPA expression can be 
induced in neurons as well as in microglia. This system is involved in many normal neural 
functions, such as neuronal plasticity, learning, and memory (Wang et al. 2006; Zhao and Pei 
2008).  
uPA and tPA are induced by Aǃ treatment in primary rat embryonic cortical cultures in 
vitro as well as in a murine model of Aǃ accumulation in vivo (Tucker, et al. 2000b). In 
addition, it plasmin degrades both non-aggregated and aggregated Aǃ40 (Tucker, et al. 
2000a), and also degrades Aǃ42, preventing Aǃ42 aggregation into beta-pleated sheet 
structures (Exley and Korchazhkina 2001). Plasmin also inhibits Aǃ toxicity, reduces Aǃ 
deposition in vitro, and inhibits Aǃ fibrillogenesis (Tucker, et al. 2002). The anti-
amyloidogenic effect of plasmin is further enhanced by its capacity to increase the 
processing of human APP, and efficiently degrading secreted amyloidogenic and non-
amyloidogenic APP fragments. Consistent with these observations, brains from AD 
patients contain reduced levels of plasmin (Ledesma, et al. 2000). Moreover, Aǃ injected 
into the hippocampus of mice lacking either tPA or plasminogen persists causing 
activation of microglial cells and neuronal damage. Conversely, Aǃ injected into wild-
type mice is rapidly cleared and does not cause neuronal degeneration (Melchor, et al. 
2003). Assembly of Aǃ42, on the other hand, seems to promote the up-regulation of the 
tPA/plasminogen proteolytic system, which can modulate the deposition of amyloid 
plaques in vivo, in a negative feedback mechanism (Lee, et al. 2007). 
3.7 Matrix metalloproteinases  
Matrix metalloproteinases (MMPs) are zinc- and calcium dependent endopeptidases, 
produced by neurons and glial cells. Metalloproteinase 2 (MMP-2) can be detected in the 
walls of some blood vessels and scattered white matter glia. Metalloproteinase 3 (MMP-3) is 
present in and around some neurons and within occasional amyloid plaques, and 
metalloproteinase 9 (MMP-9) is present in many neurons. 
MMP-2 and MMP-9 all have Aǃ-degrading activity in vitro, although the Aǃ degrading 
activity of these MMPs has not received so much attention in vivo. However  MMP-2 and 
MMP-9 activity are elevated in homogenates of hippocampal tissue from AD brains, and 
several cell types (glial, neuronal and vascular) up-regulate endogenous MMP-2 -3 and -9 
expression in response to Aǃ  stimulation (Deb and Gottschall 1996; Miners et al. 2008b; 
Gottschall 1996). 
MMP-2 also known as gelatinase A/type IV collagenase/matrix hydrolyses Aǃ40 and 
Aǃ42 peptides at Lys 16-Leu 17, at Leu 34-Met 35, and Met 35-Val 36 peptide bonds 
(Roher, et al. 1994). Besides its Aǃ degrading activity, MMP-2 has also beta-secretase 
activity (LePage, et al. 1995). In AD brains, MMP-2 is present in the reactive microglia 
located in the center of senile plaques, and in Schwann cells (Yamada, et al. 1995). Aǃ 
stimulates the expression and activation of MMP-2 to a large extent due to the increased 
expression of membrane type-1 (MT1)-MMP expression, the primary MMP-2 activator 
(Jung, et al. 2003).  
There seems to be a complex regulation of MMP2 expression by oligomeric Aǃ in astrocytes. 
Oligomeric Aǃ directly down-regulates MMP2 expression and activation in astrocytes. 
However, it also induces the production of pro-inflammatory cytokines which stimulate 
production of  MMP2 (Li, et al. 2011). 
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Increased MMP-9 immunolabelling has been detected in neurons of  AD patients, as well as 
in neurofibrillary tangles, plaques and blood vessel walls, but not in granular neurons or 
glial cells. MMP-9 is also detected in the vicinity of extracellular amyloid plaques 
(Backstrom, et al. 1996). MMP-9, unlike ECE-1, NEP and IDE, is capable of cleaving 
aggregated Aǃ fibrils (Miners et al. 2008b). It cleaves Aǃ at several sites, predominantly at 
Leu34-Met35 within the membrane-spanning domain (Backstrom et al. 1996; Yan, et al. 
2006). The presence of the apoE4 significantly dampens Aǃ-induced MMP-9 in primary 
cultures of rat astrocytes. This effect may affect Aǃ clearance and promote Aǃ deposition in 
AD brains (Guo, et al. 2006).  There is also evidence that reduction of Aǃ levels through the 
action of MMP-9 may also result from the direct processing of cell surface APP with an 
alpha-secretase like activity, substantially reducing the levels of secreted Aǃ peptide 
(Talamagas, et al. 2007). 
Aged APP/presenilin 1 mouse astrocytes surrounding amyloid plaques, showed 
enhanced expression of MMP-2 and MMP-9. Astrocyte-conditioned medium obtained 
from these animals degraded Aǃ, producing several small fragments. In the brains of 
MMP-2 and MMP-9 KO mice, significant increases in the Aǃ levels were found in 
comparison to wild-type controls. This study reinforces previous in vitro evidences that 
MMP-2 and -9 may contribute to extracellular brain Aǃ clearance through the degradation 
of Aǃ (Yin, et al. 2006). 
Several MMPs polymorphisms have been examined in relation to the  risk of developing 
dementia with controversial results (Baig, et al. 2008; Helbecque, et al. 2007; Reitz, et al. 
2008; Reitz, et al. 2010). MMPs may also be considered potential plasmatic and cerebrospinal 
fluid markers of AD as the levels of MMP-3 in the plasma and CSF of AD patients was 
found higher than in controls, whereas MMP-2 was significantly decreased in CSF but 
unchanged in plasma (Horstmann, et al. 2010). 
3.8 Transthyretin  
Transthyretin (TTR) is a 55 kDa homotetrameric protein secreted mainly by the liver and 
choroid plexus into the plasma and CSF, respectively (Soprano, et al. 1985). The name 
“transthyretin” discloses its dual physiological role as a carrier for thyroid hormones 
(Woeber and Ingbar 1968) and retinol, the latter through the binding to retinol-binding 
protein  (Goodman 1985). TTR plasma concentration is age dependent and in healthy 
newborns it is about half of that in adults (Stabilini, et al. 1968; Vahlquist, et al. 1975), 
varying from 20 to 40 mg/ dL. In spite of the low TTR levels in CSF (~2 mg/ dL), the 
choroid plexus is presented as the major site of TTR expression, expressed as a ratio of 
tissue/mass, corresponding to a 30-fold higher than that found in plasma and represents 
20% of the total CSF proteins (Weisner and Kauerz 1983). 
Over a hundred TTR mutations have been associated with Familial Amyloid 
Polyneuropathy (FAP), some of which are very common in Portuguese patients, such as the  
valine at position 30 substituted by a methionine (TTR V30M) (Saraiva, et al. 1984), others 
provide a very aggressive phenotype, such as the TTR L55P (Jacobson, et al. 1992).  
Curiously, TTR T119M was described as an example of a non-aggressive mutation that 
inclusively has a protective role against the disease (Almeida, et al. 2000).  
The first report that associates TTR to Aǃ and AD as a protective molecule is from 
Schwarzman et al. who describes the capacity of normal CSF to inhibit amyloid formation  
and concluded that TTR was the major Aǃ binding protein in the CSF, that could also 
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decrease the aggregation state of the peptide and its toxicity (Schwarzman, et al. 1994). 
Prior to this finding, TTR was found associated to senile plaques, NFTs and 
microangiopathic lesions (Shirahama, et al. 1982). The sequestration hypothesis was 
raised suggesting that normally produced Aǃ is sequestered by certain extracellular 
proteins, thereby preventing amyloid formation and Aǃ cytotoxicity; when sequestration 
fails amyloid formation occurs (Schwarzman and Goldgaber 1996). The observation that 
TTR is reduced in the CSF of AD patients further supported the idea of a TTR protective 
role in this pathology (Serot, et al. 1997). Authors also observed a decrease in TTR levels 
with age which could be related to the epithelial atrophy in the choroid plexus. Along 
time several reports described TTR decrease in CSF of AD patients (Davidsson, et al. 2002; 
Serot et al. 1997; Gloeckner, et al. 2008; Hansson, et al. 2004) although it remains unclear 
whether this reduction is restricted to AD, or on the contrary is common to other 
neurodegenerative disorders (Chiang, et al. 2009). It is also uncertain if the TTR decrease 
in the CSF happens early in disease development (or even before symptoms appears) or if 
it is a latter event, and thus studies involving patients with mild cognitive impairment 
(MCI) and early-staged probable AD patients are needed. 
Other studies using a transgenic model of Caenorhabditis elegans expressing Aǃ42 supported 
a TTR role in AD as administration of TTR rescued the neurodegeneration observed in this 
model (Link 1995). Mammalian models used to recapitulate AD features were never 
completely successful as AD transgenic mice did not show NFTs and demonstrate little or 
no neuronal cell loss (Holcomb, et al. 1998; Hsiao, et al. 1996; Irizarry, et al. 1997a; Irizarry, et 
al. 1997b; Stein and Johnson 2002). However, in some of the models, animals showed 
increased TTR expression in the hippocampus (Stein and Johnson 2002); TTR was then 
described to be a survival gene (Stein and Johnson 2002) and although this work is 
controversial because TTR expression is thought to be confined to the choroid plexus and 
meninges (in the case of the brain), authors further showed that when a chronic infusion of 
an antibody against TTR was applied into the hippocampus of mice expressing human APP, 
an increase of Aǃ, tau phosphorylation, neuronal loss and apoptosis were observed (Stein, et 
al. 2004). Underlying these observations is, according to authors, sAPPǂ that leads to 
increased expression of protective genes, such as TTR, to confer neuroprotection (Stein et al. 
2004). Other studies, using transgenic APP mice hemizigous for endogenous TTR showed 
accelerated Aǃ deposition (Choi, et al. 2007), while double transgenic mice for APP and TTR 
presented lower deposition (Buxbaum, et al. 2008). However, in other models, TTR was 
described to have the opposite effect and was associated with increased vascular Aǃ 
deposition (Wati, et al. 2009). 
Regarding the nature of TTR/Aǃ interaction, different researchers confirmed TTR binding 
to Aǃ (Carro, et al. 2002; Liu and Murphy 2006; Costa, et al. 2008) not only to the monomer 
but also to Aǃ oligomers and fibrils, raising the hypothesis that TTR may be involved in the 
formation of senile plaques (Costa et al. 2008); TTR was also able to inhibit and to disrupt 
Aǃ fibrils. However, which TTR conformation binds Aǃ peptide is still controversial. Du 
Murphy et al.  showed that TTR tetramers interact preferably with Aǃ aggregates rather 
than Aǃ monomers enhancing Aǃ aggregation, whereas TTR monomers arrest Aǃ aggregate 
growth (Du and Murphy 2010). On the other hand, studies by Costa et al. (Costa et al. 2008) 
showed that soluble Aǃ binds to different TTR variants correlating negatively with the 
amyloidogenic potential of the TTR mutant. Thus, TTR119M presented the highest affinity 
to Aǃ, contrarily to what was observed by Du and Murphy (Du and Murphy 2010). Other 
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studies also indicated a different relation between TTR variant/amyloidogenic potential and 
binding to the peptide, with amyloidogenic mutants binding less to Aǃ peptide and 
inhibiting less its aggregation (Schwarzman, et al. 2004). In this work it was also shown that 
TTRs were functional tetramers. Hence, other studies are necessary to completely 
understand the nature of the TTR/Aǃ interaction, concerning both Aǃ and TTR species 
involved. Structural analysis, obtained from computer-assisted modeling (Schwarzman et 
al. 2004) predicted the existence of an Aǃ binding domain on the surface of each TTR 
monomer; residues 30-60, especially the 38-42 region of TTR seemed to be the key structure 
of the Aǃ binding domain  (Schwarzman and Goldgaber 1996; Schwarzman, et al. 2005). Du 
and Murphy, identified the A strand, in the inner ǃ-sheet of TTR, as well as the EF helix, as 
regions of TTR that are involved with Aǃ association (Du and Murphy 2010).  
The discussion on the TTR interaction with Aǃ and consequent inhibition of aggregation and 
toxicity reduction raised the hypothesis that mutations in the TTR gene or conformational 
changes in the protein induced by aging, could affect the sequestration properties. A study 
was conducted with the aim of identifying mutations in the TTR gene in the AD population 
but no correlation was found (Palha, et al. 1996). Finally, and concerning the mechanism 
underlying TTR protective role in AD, Costa and colleagues found that TTR is able to 
proteolytically process Aǃ peptide (Costa et al. 2008). Regarding TTR ability to degrade Aǃ, 
several cleavage sites were identified and the newly generated Aǃ peptides shown to have 
decreased amyloidogenic potential, when compared to the full length counterpart (Costa et al. 
2008); TTR is also able to degrade aggregated forms of the peptide and inhibition of the TTR 
activity resulted in increased Aǃ fibril formation (Costa et al. 2008). 
3.9 Gelsolin 
Gelsolin can be found both as an intrinsic cytoplasmic protein and as a secreted protein in 
plasma and CSF (Kwiatkowski, et al. 1985). Intracellular gelsolin regulates actin 
polymerization by binding to actin, and it also caps and breaks the actin filaments (Janmey, 
et al. 1985; Matsumoto, et al. 2003). Secreted (plasma/CSF) and intracellular gelsolin 
originate from the alternative splicing of a single gene, but their disulphide structure is 
different with recognised functional implications. All of the five cysteine (Cys) residues 
present in human cytoplasmic gelsolin are free thiols, whereas in plasma/CSF gelsolin, 
three Cys residues are free thiols and the other two Cys residues are disulfide-linked (Wen, 
et al. 1996). The five free thiol groups are likely to confer anti-oxidant properties to the 
molecule. Secreted gelsolin has an extension of 25 amino acids at its N-terminal, which is 
absent in the cytoplasmic form (Chauhan, et al. 2008).  
Gelsolin found in the CSF may originate from oligodendrocytes or microglia (Chauhan et al. 
2008). It was also suggested that choroid plexus may be responsible for the presence of 
gelsolin in CSF (Matsumoto et al. 2003), where it may have also an important function 
counteracting the neurotoxicity of Aǃ (Antequera, et al. 2009; Vargas, et al. 2010). 
Plasma and cytosolic gelsolin both bind Aǃ and the Aǃ -gelsolin complex exists in the 
plasma and in the cytosol (Chauhan, et al. 1999; Ji, et al. 2008). Both inhibit the fibrillation of 
Aǃ, and defibrillate preformed fibrils (Ray, et al. 2000). In addition it has been demonstrated 
that when administered to transgenic mouse models of AD reduces the Aǃ40/Aǃ42 and the 
amyloid load (Hirko, et al. 2007; Matsuoka, et al. 2003). Therefore, gelsolin may also be 
looked as a potential therapeutic agent against AD.   
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3.10 Alpha2-macroglobulin 
Alpha2-macroglobulin (a2M) is a 720 kDa soluble glycoprotein composed of four identical 
180 kDa subunits, each encoded by a single-copy gene on human chromosome 12. Each 
subunit contains at least five binding sites: the bait region, the internal thiol ester, the 
receptor binding site, the Aǃ binding site, and the zinc binding site. The bait region, the 
internal thiol ester and the receptor binding site are crucial for the activation and 
internalization of a2M. The bait region binds any known protease. The four bait regions in 
the tetramer are in close contact and get cleaved by the bound proteases, triggering 
activation of a2M. This conformational change results in the exposure of the four thiol 
esters, and of the four receptor binding sites, to the extracellular environment. The receptor 
binding site of each monomer, a 27 residue consensus sequence located at their C-terminal 
tail, will then bind to the receptor and mediate the internalization of the complex. The Aǃ 
binding site is located between the bait and the receptor binding regions of each monomer 
(Borth 1992; Du, et al. 1997; Hughes, et al. 1998; Kovacs 2000).  
Binding to Aǃ42 occurs with high affinity (Kd= 3.8 x 10-10 M)  and protects the peptide from 
proteolysis by exogenous trypsin, suggesting  that a2M may function as a carrier protein for 
Aǃ and may serve to regulate clearance of Aǃ from such tissues as the brain (Du et al. 1997; 
Hughes et al. 1998). a2M co-incubated with Aǃ significantly reduces aggregation and fibril 
formation in vitro, and  cultured fetal rat cortical neurons are less vulnerable to the toxic 
actions of  Aǃ  following pretreatment with a2M, being likely that a2M has the capacity to 
keep Aǃ in a soluble state, preventing fibril  formation and associated neurotoxicity (Du, et 
al. 1998). a2M also inhibits both Aǃ fibril formation and Aǃ -induced cytotoxicity in PC12 
cells (Monji, et al. 2000). The inhibition of the formation of amyloid fibrils are probably due 
to the interaction of a2M   with prefibrillar species  to maintain the solubility of Aǃ (Yerbury, 
et al. 2009), and therefore their aggregation state in the extracellular milieu. In addition, Qiu 
et al described a serine protease that binds to a2M to form a stable high molecular weight 
complex capable of efficiently cleaving Aǃ (Qiu, et al. 1996). This serine protease-a2M 
complex was capable of proteolytically digesting both Aǃ40 and Aǃ42, resulting in 
disruption of the central region of the peptide (residues 10–35), which is believed to mediate 
the conformational change that underlies Aǃ self-aggregation (Qiu et al. 1996).  
a2M is also a physiological ligand for the low-density lipoprotein receptor-related protein 
(LRP) abundantly expressed in the CNS. The a2M/Aǃ complexes can be degraded by 
glioblastoma cells and fibroblasts via LRP, but the degradation of free Aǃ must be mediated 
via an LRP-independent pathway. These results suggest that LRP can function as a 
clearance receptor for Aǃ via a2M (Narita, et al. 1997). The effect of self-aggregation and 
LRP-1 ligands on the elimination of human Aǃ 40 from the rat brain across the blood-brain 
barrier has been investigated recently. In the first instance it was demonstrated that the 
elimination rate of 125I hAǃ40 dimer was 92.7% decreased compared to the  125I hAǃ40 
monomer. When pre-incubated with LRP-1 ligands, such as activated a2M, apolipoprotein 
E2 (apoE2), apoE3, apoE4, and lactoferrin, the elimination of 125I hAǃ40) was reduced. There 
seems that dimerization and LRP-1-ligand complex formation prevents the elimination of 
Aǃ40 from the brain across the blood-brain barrier (Ito, et al. 2007).  
There is also an over-representation of a common a2M polymorphism, Val1000 
(GTC)/Ile1000 (ATC) in AD patients, which correlates with an increase in Aǃ burden 
(Kovacs 2000; Liao, et al. 1998), further sustaining the importance of a2M in Aǃ 
clearance. 
www.intechopen.com
 Key Enzymes and Proteins in Amyloid-Beta Production and Clearance 
 
69 
3.11 Apolipoprotein E 
From all the proteins and peptides associated with  AD and amyloid beta metabolism,  
apolipoprotein E (ApoE) is probably the most thoroughly studied, and several recent 
reviews give excellent and comprehensive overviews about its structure and function 
(Zhong and Weisgraber 2009a, b), and the pathways in which it is involved in AD (Kim, et 
al. 2009), either Aǃ dependent or Aǃ independent (Huang 2010; Mahley, et al. 2006). 
Therefore, this section will just give a brief overview about ApoE and will focus only on its 
association with AD via Aǃ dependent pathways. 
ApoE is a 34,2 kDa glycoprotein containing 299 amino acids. The protein contains two 
structural domains that are responsible for different functions of apoE. The amino-terminal 
domain (residues 1-191) contains the lipoprotein receptor binding region (residues 136-150), 
and the carboxyl-terminal domain (residues 216-299) contains the major lipoprotein (lipid) 
binding domain.  
There are three common isoforms of ApoE, ApoE2, ApoE3 and ApoE4, which are encoded 
by three alleles (e2, e3 and e4, respectively) of a single gene. Sequence differences among the 
ApoE isoforms reside only on amino acids 122 or 158 which may be cysteine or arginine, but 
are sufficient to determine significant functional consequences (Huang 2010; Mahley et al. 
2006).  
ApoE4 is the major known genetic risk factor for AD and as much as 65–80% of all AD 
patients are ApoE4 carriers. This allele is over-represented in late-onset familial AD in 
several populations and in late-onset sporadic AD (Farrer, et al. 1997). In addition,  as the 
number of Apo E alleles increases,  the risk of onset of AD also increases while the age of 
onset decreases; as the number of ApoE4 alleles increases from 0 to 2, the risk of developing 
late-onset AD increases from 20% to 90%, and the mean age of onset decreases from 84 to 68 
years (Corder, et al. 1993; Frangione, et al. 1996). The N and C terminal domains of ApoE 
interact in ApoE4 (called domain interaction), which is mediated by the formation of a salt 
bridge between Arg-61 in the N- terminus and Glu-255 in the C- terminus of ApoE4. This 
interaction might be the molecular basis for the detrimental effects of ApoE4 in AD 
pathogenesis (Huang 2010). 
ApoE is expressed in several organs but is mainly expressed in the liver, followed by the 
brain. Non-neuronal cells, mainly astrocytes and to some extent microglia, are the major cell 
types that express apoE in the brain (Boyles, et al. 1985; Pitas, et al. 1987). Neurons also 
produce ApoE under certain conditions, particularly in response to brain injury (Boschert, et 
al. 1999) . 
ApoE (E2 and E3) are important for the distribution of lipids among cells throughout the 
body and within the CNS, where the principal apolipoproteins are, and where they 
transport lipids and cholesterol for cell repair and neurite outgrowth. These properties are 
not shared by Apo E4 which seems to counteract the features of Apo E2 and ApoE3 with 
detrimental effects (Mahley et al. 2006).  
ApoE  is also essential for astrocytes to bind, internalize and degrade Aǃ deposits 
(Koistinaho, et al. 2004). ApoE binds  Aǃ with high affinity. It was demonstrated that lipid-
free ApoE4 and ApoE3 form stable complexes with Aǃ, with ApoE4 being more effective in 
the formation of the complex, but inducing a pathological ǃ-sheet conformational change in 
Aǃ ((Wisniewski and Frangione 1996). This interaction requires the N-terminal and the C-
terminal domains, and there are strong indications that the interaction is affected by the 
lipid content (Weisgraber and Mahley 1996).  
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ApoE, but not ApoE4 plays a role in facilitating the proteolytic clearance of soluble Aǃ from 
the brain. The endolytic degradation of Aǃ peptides within microglia by NEP and related 
enzymes is dramatically enhanced by ApoE.  Similarly, Aǃ degradation extracellularly by 
IDE is facilitated by ApoE. The capacity of ApoE to promote Aǃ degradation is dependent 
upon the ApoE isoform and its lipidation status. The enhanced expression of lipidated 
ApoE, through the activation of liver X receptors, stimulates Aǃ degradation (Jiang, et al. 
2008). 
In contrast, Apo E4 inhibits Aǃ clearance and stimulates Aǃ deposition (Huang, et al. 2004). 
It also enhances Aǃ production and potentiates Aǃ induced chromosomal leakage and 
apoptosis (Mahley and Huang 2006). In addition, ApoE4 enhances Aǃ42 oligomer induced 
toxicity (Manelli, et al. 2007). Taken together these observations sustain the effects of ApoE4 
in the enhancement of the overall Aǃ burden via interaction with the peptide.  
3.12 Metallothioneins 2 and 3 
Metallothioneins (MTs) were discovered as cadmium binding proteins in equine kidney 
cortex. MTs is a generic name for a superfamily of low molecular weight cysteine- and 
metal-rich proteins with high affinity for divalent metals, such as zinc, cadmium and copper 
with four major isoforms, MT-1 to MT-4, identified in humans. They occur in all living 
organisms from the simplest forms of life, such as prokaryotes to the most complex, such as 
higher plants and vertebrate animals. It is clear that MTs are multipurpose proteins with 
unquestionable metal binding and anti-oxidant properties. In addition, there is increasing 
evidence that MT-1 and MT-2 (MT-1/2), and MT-3 display such diverse physiological 
actions as inhibition of pro-apoptotic mechanisms, enhancement of cell survival, tissue 
regeneration, and have anti-inflammatory properties. Concurrent with this wide array of 
functions, MT-1/2 have been implicated in neuroprotection and neurodegeneration, and 
particularly in AD (Hidalgo, et al. 2009; Penkowa, et al. 2006).  
It is interesting that a considerable body of work has related an increase of MT-1/2 brain 
levels with aging and AD. In AD patients elevated levels of cytokines and IL-1 may induce 
MT-1/2 production in astrocytes. Studies in animal models of AD, showed that the MT-1/2 
levels were higher, when compared to WT mice, while MT-3 levels were unaltered or 
reduced, suggesting that these proteins may have a relevant role in providing long term 
protection against inflammation (Hidalgo  et al. 2009). This up-regulation of MT-1/2 in 
animal models of AD may have detrimental consequences in Aǃ clearance as MT-2 
diminishes the binding of TTR to Aǃ (Martinho, et al. 2010). Considering TTR an Aǃ 
scavenger as explained above, a less efficient removal of Aǃ would be expected when MT-2 
levels are increased, and this appears to be the case in AD.  Furthermore, inhibition of 
homeodomain interacting protein kinase 2 activity in AD patients, might be involved in p53 
misfolding, most likely through MT-2A upregulation (Lanni, et al. 2010). In addition, it was 
also shown that MT-2A may also prevent copper-mediated Aǃ aggregation and 
neurotoxicity, by a mechanism which primarily involves a specific metal exchange 
interaction between Zn7.MT-2A and Cu(2).Aǃ, and subsequent inhibition of H2O2 
generation (Chung, et al. 2010).  Furthermore, a metal swap between Zn7.MT-3 and soluble 
and aggregated Aǃ1–40–Cu(II) abolishes  ROS production and related cellular toxicity 
(Meloni, et al. 2008). 
These studies relating metal exchange and Aǃ aggregation, conducted to a recent interest in 
the use of metal-chelation drugs as a potential therapy for AD. For example, the 
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administration of the copper and zinc chelating drug, clioquinol, prevents plaque formation 
in transgenic AD mice (Hegde, et al. 2009).  
Since the discovery of MT-3 as a growth inhibitory factor, with reduced expression levels in 
AD brains compared to age-matched controls, several studies provide evidence that MT-3 is 
related to the aetiology of AD. Some studies indicate that MT-3 may potentially promote the 
clearance of Aǃ plaques, while others show an opposite trend or even no differences 
(Howells, et al. 2010). MT-3 alone antagonizes the toxic effect of Aǃ because it inhibits the 
formation of SDS-resistant Aǃ aggregates, thereby protecting cortical neurons from its toxic 
effects. Both the full-length and the N-terminal domain of MT-3 promote neuron survival at 
low concentrations but inhibited it at high concentrations. These observations suggest that 
the anti- Aǃ activity of MT-3 is different from its neuronal growth inhibitory activity. Other 
possible mechanisms underlying the protection of MT-3 from Aǃ toxicity may be related to 
its interaction with TTR by improving its Aǃ degrading capacity (Martinho et al. 2010). 
4. Conclusion 
The extracellular neuritic plaque deposits of amyloid found in AD brains contain Aǃ, and 
according to the amyloid cascade hypothesis, the accumulation of Aǃ peptide,  can trigger 
gradual synaptic alterations, astrocytic and microglial activation, and modification of the 
soluble tau protein into insoluble paired helical filaments, with progressive neuronal loss 
and cognitive failure (Hardy and Selkoe 2002). The cascade hypothesis suggests that 
stopping or slowing formation of the Aǃ plaques would delay the onset of the disease 
symptoms. Therefore, it is crucial to thoroughly elucidate the regulation of Aǃ production 
and clearance to design new and effective therapies against AD. 
APP, takes a central position in AD pathogenesis, as Aǃ arises from its proteolytic cleavage 
through the sequential action of ǃ- and Ǆ-secretase. APP is first cleaved by either ǂ- or ǃ-
secretase at the ǂ- or ǃ-sites, respectively, which lie in the extracellular domain of APP. 
These proteases originate: soluble APPǂ (sAPPǂ, for ǂ-secretase) or soluble APPǃ (sAPPǃ, 
for ǃ-secretase), which are released to the extracellular space, and a membrane anchored C-
terminal end (C83 for ǂ-secretase or C99 for ǃ-secretase). Ǆ-cleavage of C99, generates the 
Aǃ peptide. This pathway is known as the amyloidogenic pathway. Misregulation of all the 
intervenients in this process may lead to Aǃ accumulation. If APP cleavage by ǃ-secretase or 
Ǆ-cleavage of C99 is more effective than ǂ-secretase, then the all process shifts into the 
accumulation of Aǃ. Also if APP synthesis is enhanced, as it is the case of several mutated 
forms of APP associated with early onset AD, the production of Aǃ is also increased with 
similar results (Ertekin-Taner 2007). So, alterations in APP synthesis and processing by both 
secretases, or downstream in the Ǆ-secretase complex action, may account for more severe 
forms of disease. Another good example of that are the mutations associated with 
presenilins 1 and 2 , which are part of the Ǆ-secretase complex, known to be responsible for 
early onset inherited forms of AD (Ertekin-Taner 2007). 
Once Aǃ has been produced, other important players come into action (Figure 2). These are 
all the enzymes and proteins that, either by directly cleaving Aǃ into less harmful peptides 
or making them more prone to proteolysis or less susceptible to aggregation through 
protein-protein interactions, will reduce the Aǃ load in vulnerable areas of the brain.  
Reduced degradation of Aǃ by proteases is generally accepted to enhance plaque pathology 
in AD brains, and may depend on several factors such as decreased mRNA expression or 
decreased protein levels or activity, either in the brain cortex, hippocampus or in brain 
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microvessels;  and  post-translational modifications, such as oxidation and deposition of the 
enzymes in the diseased brain with consequent loss of its native structure and functionality 
(Dorfman et al, 2010.).  
IDE and NEP are well accepted as Aǃ degrading enzymes, but although few studies 
compare the relative contribution of each of these enzymes to the overall Aǃ load, NEP 
seems to be the major protease involved in Aǃ degradation. In transgenic mice models of 
familial AD, over-expression of IDE or NEP prevents amyloid plaque pathology and 
consequent early death (Leissring, et al. 2003) indicating that degradation of Aǃ by these 
metalloproteinases may be of high therapeutic interest for AD patients. A recent study 
carried out in AD patients showed that, NEP mRNA, protein levels, and activity are 
decreased compared to normal controls without any cognitive impairment. In these 
patients IDE activity was unchanged, though mRNA levels increased. In the same study 
ECE-1 expression or activity in AD brains was not different from age-matched controls. 
Correlation analyses suggested that NEP expression was correlated with Aǃ accumulation 
and clinical diagnosis, being lower in AD than in controls, whereas no correlations of  IDE 
and ECE-1 with Aǃ levels or clinical diagnosis has been found. These findings provide 
additional support for NEP as the major protease involved in Aǃ degradation (Wang et al. 
2010).  
Age is the major risk factor for AD. Aǃ -synthesizing enzyme activities increase with age, 
coinciding with declining soluble Aǃ and increasing insoluble Aǃ (Miners, et al, 2008b.). In 
addition, there is an overall ageing-related down regulation of Aǃ degrading proteases 
which is particularly relevant for NEP but not for IDE in transgenic Tg2576 mice brains 
(Dorfman et al., 2010). Nevertheless further studies assessing the relative contribution of 
each of these enzymes , IDE, NEP, Prep, ECE, ACE and plasmin are necessary to understand 
why the system redundancy is not always effective, and which of these enzymes may be 
more adequate as candidate therapeutic targets.  
Regarding proteins with the capacity to degrade Aǃ or of interfering in the process, TTR is 
probably the most promising, with potential as a biomarker of the disease and even as a 
putative therapeutic agent. The literature shows that TTR plays an important role in the 
modulation of Aǃ aggregation and toxicity. The use of TTR as a sera biomarker for 
diagnosis purposes in AD patients should also be explored, with obvious advantages, for 
both patients and researchers, and there are already indications that sera TTR is decreased 
in AD patients when compared to age-matched controls (Han et al., 2011). Moreover, it is 
important to investigate the factors that affect TTR/A-Beta binding and/or TTR alterations 
that lead to its decreased in AD, such as protein oxidation (Biroccio et al., 2006). Further 
studies are necessary to unravel the mechanism underlying TTR protective role in AD, to 
establish if TTR decline is a cause or consequence of disease, and the cellular pathways 
involved.  
Other proteins as gelsolin, a2M and Apo E counteract Aǃ deposition through interactions 
with the peptide, but apparently none of them seem to have the capacity to cleave the 
peptide. In general these proteins bind Aǃ and the effects of these interactions translate into 
preventing Aǃ fibrillation, and eventually on disaggregation of pre-existent fibrils (gelsolin 
and a2M); binding of enzymes conferring them the capacity to degrade Aǃ (a2M) or may 
enhance the capacity of Aǃ proteases, as NEP and IDE to cleave Aǃ (ApoE). MT ½ and MT3 
bind TTR affecting its capacity to cleave Aǃ and prevent metal associated Aǃ aggregation or 
inhibit their formation. 
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The scientific achievements acquired over the past decade on all the pathways and key 
players involved in the amyloid cascade will hopefully contribute to the development of 
more adequate therapies against AD in a closer future. 
 
 
Fig. 2. Schematic diagram depicting  APP processing: key proteins in amyloid-beta 
production and clearance  (not drawn in scale). IDE- Insulin degrading  enzyme; NEP-
Neprilysin; PreP- Presequence peptidase; ECE –Endothelin-converting enzyme; ACE- 
Angiotensin-converting enzyme; MMP- Matrix metalloproteinase; TTR-Transthyretin; a2M- 
Alpha2-macroglobulin; ApoE- apolipoprotein E. 
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